Dr Andrew Grierson

PhD

Neuroscience, School of Medicine and Population Health

Senior Lecturer in Neuroscience

a.j.grierson@sheffield.ac.uk
+44 114 222 2277

Full contact details

Dr Andrew Grierson
Neuroscience, School of Medicine and Population Health
Room B25
Sheffield Institute for Translational Neuroscience (SITraN)
385a Glossop Road
Sheffield
S10 2HQ
Qualifications

2009 –present: Senior Lecturer
2001 - 2008: Lecturer, University of Sheffield
1997 - 2001: Postdoctoral Research Associate, Institute of Psychiatry, Kings College London
1994 - 1997: Postdoctoral Research Associate, University of Amsterdam, Netherlands
1991 - 1994: PhD (Molecular Genetics) University of Sheffield
1988 - 1991: BSc (Genetics) University of Sheffield

Research interests

Research in my laboratory concerns identifying the molecular mechanisms underlying the regulation of axonal transport in health and disease. In particular we are investigating the involvement of axonal transport in diseases including motor neurone disease (MND) and hereditary spastic paraplegia (HSP).

In addition we are developing and characterising novel vertebrate models of neurodegeneration in zebrafish and mouse. With support from the NC3Rs we are refining the widely used SOD1G93A model of motor neuron disease.

Current projects

  • Preclinical testing of HDAC6 inhibition in a zebrafish model of CMT2A (Hereditary Neuropathy Foundation)Investigating the function of the C9ORF72 protein in motor neuron disease (University Studentship)

  • Preclinical assessment of histone deacetylase 6 (HDAC6) inhibition as a therapy for hereditary spastic paraplegia (Spastic Paraplegia Foundation)

  • ANIMPACT: An ethical, legal and practical perspective on the impact of a new regulatory framework for the scientific use of animals on research and innovation (European Union) Zebrafish C9orf72 loss of function models of ALS (MND Association)

  • Role of C9ORF72 in proteostasis. (De Vos PI) (Thierry Latran Foundation) ROLE OF MITOCHONDRIA IN C9ORF72-RELATED ALS/MND (De Vos is PI) (MND Association)

  • Preclinical assessment of spastin gene replacement therapy as a treatment for hereditary spastic paraplegia (Spastic Paraplegia Foundation)

Research collaborations

  • Pamela Shaw, Academic Neurology Unit, University of Sheffield
  • Bob Johnston, University of Sheffield
Publications

Journal articles

Chapters

Conference proceedings papers

  • Mohammedeid A, Bhargava A, Godena VK, Kong S, Tennore R, Grierson AJ, Xu J, Shaw PJ, Azzouz M & Ning K (2019) Arfaptin-2 as a therapeutic target for amyotrophic lateral sclerosis (ALS). HUMAN GENE THERAPY, Vol. 30(8) (pp A19-A20) RIS download Bibtex download
  • Hewamadduma C, Grierson A, Higginbottom A & Shaw P (2015) Fibroblasts from patients with amyotrophic lateral sclerosis (ALS) associated with mutations in tardbp gene as model of TDP-43 proteinopathy. Journal of the Neurological Sciences, Vol. 357 (pp e49-e49) RIS download Bibtex download
  • Adamson KI & Grierson AJ (2015) FISH ON DRUGS: A ZEBRAFISH PRECLINICAL MODEL FOR CMT2A. JOURNAL OF THE PERIPHERAL NERVOUS SYSTEM, Vol. 20(2) (pp 92-93) RIS download Bibtex download
  • Mohammedeid A, Ning K, Kong SC, Azzouz M & Grierson A (2014) Regulation of protein aggregation by Arfaptin2 in amyotrophic lateral sclerosis. HUMAN GENE THERAPY, Vol. 25(5) (pp A14-A14) RIS download Bibtex download
  • Hewamadduma C, Grierson A, Moens C, Pan L, Ma T, Ingham P, Ramesh T & Shaw P (2012) A novel alternative splicing event rescues the mutant tardbp phenotype in a zebrafish model of TDP-43 related Amyotrophic Lateral Sclerosis (ALS). NEUROLOGY, Vol. 78 RIS download Bibtex download
  • Hewamadduma C, Grierson A, Moens C, Pan L, Ma T, Ingham P, Ramesh T & Shaw P (2012) A novel alternative splicing event rescues the mutant tardbp phenotype in a zebrafish model of TDP-43 related Amyotrophic Lateral Sclerosis (ALS). NEUROLOGY, Vol. 78 RIS download Bibtex download
  • Hewamadduma C, Higgenbottom CAA, Moens C, Helde K, Raman R, Tennore R, Grierson A & Shaw PJ (2012) NOVEL IN VITRO AND IN VIVO MODELS OF ALS ASSOCIATED WITH TDP-43 PROTEINOPATHY. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, Vol. 83(3) RIS download Bibtex download
  • Eckmann J, Eckert SH, Leuner K, Bordet T, Pruss R, Grierson A, Shaw P, Clemens L, Nguyen HP, Mueller WE & Eckert GP (2011) Impact of Olesoxime on disease related mitochondrial membrane properties in mouse models of neurodegenerative diseases. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, Vol. 383 (pp 51-51) RIS download Bibtex download
  • Valori CF, Ning K, Wyles M, Mead RJ, Grierson AJ, Shaw PJ & Azzouz M (2010) Systemic delivery of scAAV9 expressing SMN prolongs survival in a mouse model of SMA. HUMAN GENE THERAPY, Vol. 21(10) (pp 1424-1425) RIS download Bibtex download
  • Clemens LE, Grierson A, De Vos K, Riess O & Nguyen HP (2010) FAST AXONAL TRANSPORT OF MITOCHONDRIA IS ALTERED IN HUNTINGTON'S DISEASE. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, Vol. 81 (pp A5-A5) RIS download Bibtex download
  • Sathasivam S, Grierson AJ & Shaw PJ (2005) Alterations of the Bcl-2 family oncoprotein members in a cell culture model of familial SOD1-related motor neurone disease. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, Vol. 76(1) (pp 157-157) RIS download Bibtex download
  • McDermott CJ, Grierson A, Wood J & Shaw PJ (2003) Hereditary spastic paraparesis associated with mutation in spastin (SPG4): A disorder of axonal transport?. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, Vol. 74(10) (pp 1453-1453) RIS download Bibtex download

Preprints

Research group
  • Natalie Rounding (PhD student)
  • Khlood Mehdar (PhD student)
  • Gary Shaw (Research Technician)
  • Katie Adamson (Research Technician)
  • Yolanda Gibson (PhD student)
Grants